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Introduction
The aim of treating human immunodeficiency virus (HIV)-
infected patients with combination antiretroviral therapy 
(ART) is to suppress viral replication and restore protec-
tive pathogen-specific immune responses. In some patients, 
this restoration process is dysregulated, and results in 
immunopathology that presents clinically as immune res-
toration disease (IRD).1 IRD may cause a severe inflam-
matory illness and is therefore often referred to as immune 
reconstitution inflammatory syndrome. Risk factors for 
IRD include severe immunodeficiency (CD4+ T cell count 
less than 50 × 106 cells/L) before starting ART, and the 
presence of antigens of opportunistic pathogens.2 We 
present a case of IRD in which the aberrant immune 
response was directed against a pathogen that has not 
previously been associated with IRD.
Case Report
A 60-year-old man was diagnosed with HIV infection after 
a prolonged illness. He had experienced progressive malaise, 
lethargy, and weight loss of 40 kg over 6 months. He pre-
sented to hospital after the onset of fever and rigors. Clinical 
examination revealed several squamous cell carcinomas 
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on the scalp that were infected, and hepatospleno megaly 
without stigmata of chronic liver disease. He gave a long 
history of excessive alcohol consumption.
At diagnosis, his CD4+ T cell count was 55 × 106 cells/L 
(11%) and the plasma HIV RNA level was > 100,000 cop-
ies/mL. Investigations also demonstrated pancytopenia 
with a normocytic anaemia (haemoglobin, 70 g/L), a lym-
phocyte count of 0.52 × 109/L, a neutrophil count of 
1.74 × 109/L, and a platelet count of 140 × 109/L. This was 
felt to be a manifestation of the HIV infection. A chole-
static pattern of elevated liver enzymes was detected (total 
bilirubin, 11 μmol/L; alkaline phosphatase, 400 U/L; gamma 
glutamyl transferase, 220 U/L; alanine aminotransferase, 
50 U/L). There was no laboratory evidence of viral hepati-
tis. A computed tomography scan showed hepatospleno-
megaly and multiple small, low-attenuated nodules. A 
screen for common opportunistic infections revealed only 
past exposure to Toxoplasma, Parvovirus B19, cytomegalo-
virus, and Epstein-Barr virus.
Combination ART consisting of zidovudine, lamivu-
dine, and efavirenz was commenced, with subsequent 
clinical improvement. One month after starting ART, his 
CD4+ T-cell rose to 100 × 106 cells/L (27%), and the plasma 
HIV RNA level dropped to 1, 200 copies/mL. Three 
months after starting ART, he developed a severe anaemia 
(haemoglobin, 50 g/L). Pure red cell aplasia was demon-
strated on bone marrow examination. Zidovudine was felt 
to be the main cause and ART was ceased. After the hae-
moglobin level recovered, ART was restarted. Zidovudine 
was replaced by lopinavir and ritonavir, while lamivudine 
and efavirenz were not changed. Adverse effects consist-
ing of nausea and diarrhoea on this regimen necessitated 
replacement of lopinavir and ritonavir by tenofovir.
Five months after starting ART, he became progres-
sively unwell over several weeks, culminating in a further 
hospital admission. He had developed severe vomiting, 
lethargy, and become bed-bound. On hospitalisation, he 
was cachectic, febrile, and severely dehydrated causing 
haemodynamic compromise. His CD4+ T cell count was 
75 × 106 cells/L (29%) and the plasma HIV RNA level had 
further dropped to 562 copies/mL. Inflammatory mark-
ers were elevated, with C-reactive protein at 100 mg/L 
and an erythrocyte sedimentation rate of 130 mm/hour 
(further risen from 100 mm/hour at the time of HIV 
diagnosis).
The cause of this febrile illness was not immediately 
evident from investigations that included an extensive 
search for opportunistic infections. He was nevertheless 
covered with antimicrobials that included trimethoprim-
sulfamethoxazole, azithromycin, and fluconazole. Pancy-
topenia developed later (haemoglobin, 80 g/L; lymphocyte 
count, 0.2 × 109/L; neutrophil count, 0.9 × 109/L; platelet 
count, 60 × 109/L). The bone marrow aspirate showed nor-
mal cells with no evidence of Mycobacteria on culture, 
and no detection of cytomegalovirus or Parvovirus B19 
nucleic acid. Unfortunately, the trephine specimen was 
insufficient for examination.
His condition further deteriorated with the develop-
ment of encephalopathy. This coincided with a rise in liver 
enzymes that was of a predominantly cholestatic pattern 
(total bilirubin, 70 μmol/L; alkaline phosphatase, 1,000 U/L; 
gamma glutamyl transferase, 300 U/L; alanine aminotrans-
ferase, 180 U/L). Again, no laboratory evidence of viral 
hepatitis was identified. Computed tomography scanning 
showed persisting hepatomegaly and further splenic 
enlargement to a length of 20 cm (from 16 cm). A liver 
biopsy was performed and showed multiple granulomas 
containing intracellular organisms. There were also other 
contributing factors to his deterioration. He was found to 
have hypercalcaemia that was likely caused by the granu-
lomas, with suppressed serum parathyroid hormone and 
25-dihydroxyvitamin D levels. Hyponatraemia, with sodium 
level dropping to 122 mmol/L, was also detected. Inappro-
priate antidiuretic hormone secretion syndrome was sup-
ported by a low plasma osmolality and relatively high 
urinary sodium concentration and osmolality.
Upon ascertaining that he had lived in Cyprus several 
years earlier, infections with organisms that cause granu-
lomatous inflammation, and are prevalent in that region, 
were considered. Serum antibodies against Leishmania 
donovani were detected in high titre as evidence of visceral 
leishmaniasis. Retrospective testing of stored serum taken 
at the time of HIV diagnosis returned a negative result.
A diagnosis of severe IRD associated with L. donovani 
infection was made. ART was ceased and corticosteroid 
therapy was commenced because of the severity of the ill-
ness (methylprednisolone 125 mg/day for 2 days, then 
prednisolone 1 mg/kg/day that was eventually ceased 
6 months later). Liposomal amphotericin B therapy was 
also commenced (AmBisome 150 mg/day for the first 
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week, then 200 mg every 3 weeks for the remainder of a 
3-month course of therapy). The patient showed a dra-
matic improvement in his inflammatory symptoms and 
was able to be discharged home 1 week later. The liver 
enzyme abnormalities, hepatosplenomegaly and hepato-
splenic nodules resolved over a longer period of time.
ART (abacavir, lamivudine, and efavirenz) was restarted 
2 months after discharge from hospital. This regimen was 
well-tolerated and 6 months later the plasma HIV RNA 
level was < 40 copies/mL and the CD4+ T-cell count was 
200 × 106 cells/L (19%).
Discussion
This may be the first known reported case of L. donovani 
IRD after initiation of ART for HIV infection. At the time 
of writing, only two other cases of Leishmania sp. IRD have 
been reported in association with visceral leishmaniasis.3 
Of particular interest is the occurrence of IRD associated 
with Leishmania sp. infection outside of a Leishmania-
endemic region. The patient had previously lived in 
Cyprus, but it has only recently been recognised that the 
MON-37 strains of L. donovani affects humans and dogs 
in that country.4 We were unable to investigate the sub-
species of the Leish mania species in this patient.
It is probable that this patient had visceral leishmania-
sis that contributed to the abnormal clinical and labora-
tory findings when he first presented with HIV infection, 
but this condition was not considered because these 
abnormalities could be attributed to other causes and 
he presented outside of a Leishmania-endemic region. 
At that stage of his HIV infection, severe immunodefi-
ciency had resulted in a negative serum antibody assay 
for Leishmania sp. infection when this was undertaken ret-
rospectively. However, antibodies to L. donovani were 
de tected at the time of the severe febrile illness. The high 
titre of these antibodies, and his subsequent response to 
treatment that included Leishmania eradication therapy, 
are suggestive of the restoration of a pathogen-specific 
immune response rather than a non-specific polyclonal 
response. In the absence of species confirmation by polymer-
ase chain reaction detection, or negative serology against 
other species of Leishmania, the authors concede that 
infection with other Leishmania species cannot be excluded.
This antibody response, taken together with the clini-
cal presentation and decreased plasma HIV RNA level, 
satisfy the provisional diagnostic criteria for IRD pro-
posed by French et al.2 The extremely severe inflammatory 
illness in this patient responded rapidly and dramatically 
to corticosteroid therapy and ART cessation, which is 
another characteristic of IRD. Eventual eradication of the 
L. donovani infection led to the slower resolution of his 
other clinical and laboratory abnormalities.
This case demonstrates the importance of identifying 
and treating opportunistic infections before starting ART, 
if possible. With hindsight, more rigorous consideration 
of this patient’s travel history might have led to an earlier 
diagnosis of visceral leishmaniasis. Non-antibody based 
investigations, such as liver biopsy and polymerase chain 
reaction detection, could then have proved useful in iden-
tifying the organism, thus allowing eradication of the 
Leishmaniasis before commencing ART. Our case also 
demonstrates the effectiveness of corticosteroid therapy 
in patients with severe inflammation complicating IRD.
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